Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Short-course Versus Long-course Antibiotic Treatment for Ventilator-associated Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Singh, Harsimran , Fite, Amsalu, Farooqi, M., Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Safia , Sahra, Syeda , Faran, Anna, Ahmad, Faran , Singh, H., Farooqi, M., Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, N., Shaikh, S.R.A., Cheema, Huzaifa Ahmad , Ahmad, Sharjeel , Faran, A., Torres, Antoní

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3719-A3719

10.1164/ajrccm.2025.211.abstracts.a3719 Get It

Abstract Rationale: Current guidelines recommend a short course of antibiotic therapy for ventilator-associated pneumonia (VAP) caused by non-fermenting gram-negative bacilli (NF-GNB). However, this approach has been associated with an increased risk of pneumonia recurrence. This meta-analysis aims to address inconsistencies in the literature and evaluate the efficacy of short-course versus long-course antibiotic therapy for VAP, particularly in cases due to NF- GNB. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing short versus long courses of antibiotic therapy in patients with VAP. The primary outcomes were the risk of all-cause mortality and pneumonia recurrence. Data were analyzed using RevMan 5.4, with risk ratio (RR) and mean difference (MD) as effect measures. Results: Our pooled analysis included seven RCTs. There was no significant difference in all- cause mortality between short- and long-course antibiotic regimens (RR 1.02; 95% CI: 0.88-1.18; Figure 1). However, a short course of antibiotics increased the incidence ofpneumonia recurrence, particularly in patients with VAP due to NF-GNB (RR 1.64; 95% CI: 1.18-2.29; Figure 1). There were no significant differences between the two regimens regarding the duration of mechanical ventilation (MD 0.01 days; 95% CI: -0.51 to 0.53 days), ICU (MD 0.10 days; 95% CI: -1.00 to 1.20 days) and hospital stay (MD -0.63 days; 95% CI: -3.18 to 1.91 days), or subsequent infection with or acquisition of resistant organisms (RR 0.89; 95% CI: 0.63-1.24). Conclusions: Our meta-analysis suggests that while a short course of antibiotics increases the risk of pneumonia recurrence in NF-GNB VAP, it does not impact mortality compared to a longer course. The clinical significance of the increased recurrence of pneumonia remains uncertain, as it did not result in worse clinical outcomes. A practical approach incorporating validated clinical criteria and biomarker thresholds to guide the duration of antibiotic therapy may be more effective for patients with NF-GNB VAP. Larger RCTs are needed to drawdefinitive conclusions in this population.
Inhibition of Candida Auris Phosphoglucomutase – A Novel Therapeutic Target
Barwatt, J.W., Pellegrino, Madeline R., Barwatt, Joseph , Kottom, Theodore J. , Limper, Andrew H.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3715-A3715

10.1164/ajrccm.2025.211.abstracts.a3715 Get It

Abstract INTRODUCTION Candida auris has emerged as a global pathogenic yeast that disproportionately affects patients in healthcare settings. Infection ranges from localized skin infections to severe bloodstream infections. Multidrug resistance, hardiness on environmental surfaces, and the ability to persist as a colonizer in both sick and healthy patients enables it to spread rapidly in healthcare settings leading to significant morbidity and mortality. Multidrug resistance has led to limited effective therapies and necessitates the need for novel therapeutic options. Here we evaluate the efficacy of ISFP10, an antifungal compound with a novel mechanism of action, against C. auris. ISFP10 inhibits fungal phosphoglucomutase (PGM), an enzyme required for production of substrates for fungal cell wall synthesis (Figure 1). METHODSMIC Testing The compound ISFP10 was submitted to the National Institute of Allergy and Infectious Diseases Therapeutic Development Services for half-maximal and maximal inhibitory concentration (IC50/IC100) testing. C. auris isolates were tested using typical drug-dilution methods. Saccharomyces cerevisiae – C. auris PGM Growth Curve Testing This proof of mechanism assay was instituted to isolate PGM in Saccharomyces for growth curve testing. The Candida auris PGM was cloned into pYES2.1 downstream of an inducible galactose promoter. This plasmid was transformed into S. cerevisiae. C. auris PGM plasmid-containing S. cerevisiae was incubated for 24 hours in 2% glucose minimal media. Using absorbance readings, the inoculum was normalized to 5x105 cells/mL in galactose-containing media. The inoculum was plated onto a 96-well plate in a drug-dilution scheme with ISFP10 at concentrations ranging from 200uM to 6.25uM along with DMSO control wells. Plates were incubated at 30° C for 72 hours in a spectrophotometer with absorbance readings every hour. Growth curves were plotted using GraphPad Prism software. RESULTS The half-maximal inhibitory concentrations (IC50) and maximal inhibitory concentrations (IC100) were consistently low across the three C. auris isolates. The IC50 ranged from 0.5 µg/mL to 1.0 µg/mL, while the IC100 was 1.0 µg/mL for each of the three isolates (Table 1). Growth curves demonstrated concentration-dependent inhibition of C. auris PGM plasmid-containing S. cerevisiae. Figure 2 shows full inhibition of fungal growth at 25µM with dose-dependent delayed growth at lower concentrations. CONCLUSIONS ISFP10 shows promise for inhibiting C. auris PGM in a dose-dependent pattern. It's high in vitro activity and novel mechanism of action necessitates further investigation as a potential therapeutic for C. auris.
Leveraging Social Media as a Community Engagement Tool to Disseminate Study Updates in a Mixed Methods Smoking Cessation Study Including American Indian and Alaska Native Populations
Tomah, M., Land, L., Taylor, Jennifer L. , Gifford, Shaun M., Sabaque, Corinna, Rusk, A.M., McCoy, J., Patten, Christi A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3673-A3673

10.1164/ajrccm.2025.211.abstracts.a3673 Get It

Abstract RATIONALE: Community engagement is critical in the conduct of research seeking to address healthcare disparities. Indigenous peoples (American Indians and Alaskan Natives) have the highest prevalence of cigarette smoking and commercial tobacco use among all racial and ethnic groups in the United States. Including Indigenous people as partners in the research process is critical for moving interventions to improve health forward. Engagement in the research process should be considerate of the time, travel, and ease of use for research participants and advisors. Based on feedback from community members, we launched social media pages with deidentified study updates for past participants and any interested community members to receive updates on a prospective mixed methods study designed to inform a pilot smoking cessation intervention. METHODS: Facebook and Instagram were the social media platforms identified for this study. Prior themes identified from the principal investigator's previous work and results of current study informed the development of posts. Institutional Review Board approval was granted for this community engagement method. There were no recruitment activities conducted on these pages, and all information was presented in a deidentified, thematic fashion to protect research participants. There were two social media moderators monitoring interaction with social media pages. An Indigenous artist created accompanying images to enhance engagement with posts. The content covered discussions on smoking cessation identified from the primary study along with profiles highlighting team members and allies. Posts were made at non-fixed, variable intervals from May to September 2024, and were checked bi-weekly to ensure respectful conduct. RESULTS: Between May and September 2024, ten posts were shared, including three highlighting Indigenous team members and allies and seven focused on smoking cessation discussions. Instagram had more engagement when compared to Facebook. Posts that featured Indigenous team members and allies received higher interaction when compared to those on smoking cessation alone, contributing to Instagram's overall success. CONCLUSION: Instagram was the more effective platform demonstrating higher engagement and follower growth when compared to Facebook. Of note, on both platforms, posts that highlighted team members and allies resonated well, and generated the most interaction. This not only emphasizes social media as an effective tool to engage underserved populations in the research process, but also suggests that emphasizing representation and ally-ship among research teams is impactful when engaging Indigenous audiences. This outcome exemplifies the importance of integrating cultural relevance in public health messaging when discussing thoughts and attitudes surrounding smoking cessation.
Artificial Intelligence-assisted Translation and Interpretation for Communication With Patients Who Have Language Barriers: A Systematic Review
Strechen, Inna , Chen, Christine , Nalaie, Keivan , Hassett, L., Gupta, Arjun , Karakus, S., Chen, C., Barwise, Amelia

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3643-A3643

10.1164/ajrccm.2025.211.abstracts.a3643 Get It

Abstract Rationale: Effective communication is crucial in healthcare, especially in acute care settings, so that patients/family members can understand treatment options, and share preferences and goals of care. For those with a non-English language preference (NELP), or who have difficulty communicating in English, professional interpreters are recognized as the gold standard in supporting bidirectional communication. However, interpreters are not always readily available for all languages or clinical settings prompting the exploration of other options for translation and interpretation. The recent developments in artificial intelligence (AI), specifically machine translation have enabled more accurate and emotional machine interpretation and translation. Methods: We conducted a systematic review to explore the usability and usefulness of AI-assisted interpretation and translation tools for improving communication between patients and clinicians including verbal and written communication. A comprehensive search of several databases including Ovid MEDLINE(R), Ovid Embase, APA PsycInfo, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus via Elsevier was performed, resulting in 2629 studies. We included studies evaluating tools for direct patient-clinician communication. For verbal communication, we included articles assessing speech interpretation, and for written communication, we focused on discharge instruction translation. Results: A total of 18 studies were included in the final analysis. Among these, 5 assessed the use of speech interpretation and 13 examined text translation of discharge materials. 14 (78%) studies found these novel AI tools beneficial for patient care, whereas 11 (62%) studies highlighted the risks, indicating that these tools can lead to serious mistakes with potential clinical harm. 5 (28%) studies reported participant satisfaction with the use of these tools in their care. Translation and interpretation accuracy varied notably across languages, with lower accuracy scores observed in languages with limited digital resources, such as Haitian Creole and Vietnamese. Conclusion: AI-assisted interpretation and translation in healthcare has several advantages including broader language accessibility than usual resources and potential cost savings for institutions and demonstrates evidence of patient satisfaction. However, these novel tools operate using multiple phases and each stage is prone to errors which may negatively impact patient care and outcomes.. AI-based interpretation and translation show promising potential, however, it is not yet ready for widespread clinical use, so professional language interpreters should be used whenever possible. Future studies should focus on evaluating accuracy as well as how best to integrate these technologies in real-time clinical settings without compromising patient safety and quality of care.
Cystic Lung Disease Mimic: A Case Report of ANCA Associated Vasculitis
Jokerst, Clint , Azadeh, Natalya , Zamora, Ana, Chen, John J. , Sullivan, M.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3607-A3607

10.1164/ajrccm.2025.211.abstracts.a3607 Get It

Abstract Introduction Lung involvement is common in ANCA-associated vasculitis (AAV), presenting in various forms: necrotizing granulomatous inflammation, tracheobronchial inflammation, pulmonary capillaritis and diffuse alveolar hemorrhage (DAH), interstitial lung disease (ILD), and asthma.1 Radiologic manifestations are diverse, often complicating diagnosis based on imaging alone. Typical patterns include lung nodules, cavitation, pulmonary hemorrhage, and peripheral consolidation; however, cystic-like lesions are rarely seen.2 We present a case of AAV with bilateral cystic-like lung lesions. Case presentation A 54-year-old male with childhood asthma initially presented to an outside hospital due to progressive exertional dyspnea for 6 years and dysphonia for 1 year. Initial computer tomography (CT) revealed pulmonary cysts (Figure 1), and a CT-guided biopsy of a right upper lobe cystic lesion revealed intra-alveolar hemorrhage, though pathology was non-diagnostic. He received a diagnosis of congenital cystic lung disease and prescribed Trelegy and fluticasone inhalers. He was instructed to take oral prednisone with taper whenever dyspnea recurs for presumed asthma exacerbation. His exertional dyspnea indeed respond to prednisone but not to inhalers, and it would recur a few weeks later, and his dysphonia persisted. He came to our facility for second opinion given being told lung transplantation is the only ultimate treatment in his case. Additional history revealed chronic ear infection, bilateral rupturesd tympanic membrane, chronic rhinosinusitis, and recurrent nasolacrimal duct infection. He had been on oral prednisone for 4 weeks and remained on 10mg daily. Physical exam noted inspiratory wheezing. Further workups were notable for normal eospinophils, normal renal function, positive C-ANCA and PR3, normal pulmonary function test. High-resolution CT deomnstrated numerous areas of parenchymal lucency with circumferential surrounding groundglass opacity (GGO). At this point, the diagnosis of PR3-AAV is made. Patient is subsequently referred to rheumatology for further management. Discussion The diagnosis of AAV relies on clinical, serologic, radiologic, and pathologic data. The atypical presentation may delay diagnosis, especially in cases limited to ear, nose, and throat involvement and the radiological findings are of low specificity.3 While cystic lesions in AAV-related interstitial pneumonia are documented4, this case lacked a defined cyst wall. The central lucency may present partially destroyed lung parenchyma due to GPA-related necrosis (emphysema or pneumatocele) with surrounding areas of blood products deposited from prior peri-lesional hemorrhage. Clinicians should consider a broad differentials when encounter a cystic-like lesion with thorough history-taking being essential.
Two Cases of Eosinophilic Granulomatous With Polyangiitis Presenting With Pulmonary Fibrosis
Ahmed, Nada, Baqir, Misbah , Ahmed, N.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3584-A3584

10.1164/ajrccm.2025.211.abstracts.a3584 Get It

Abstract Introduction: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is an ANCA-associated vasculitis (AAV) that causes eosinophil-rich granulomatous vasculitis affecting small vessels. While pulmonary manifestations of EGPA are diverse, development of pulmonary fibrosis is rare. We present two cases of EGPA with pulmonary fibrosis.Case 1: A 31-year-old female with refractory asthma, chronic rhinosinusitis, recurrent ear infections, presented with productive cough, dyspnea, wheeze with relief from antibiotics and steroids. Labs noted peripheral eosinophilia, elevated IgE, P-ANCA positivity with equivocally positive PR3 antibody. CT chest revealed bilateral lower lobe predominate honeycombing, traction bronchiectasis, subpleural reticulations indeterminate for UIP. Pulmonary function tests (PFTs) noted complex restriction with mildly reduced diffusion capacity of carbon monoxide (DLCO). Exhaled nitric oxide (ENO) was elevated at 132 parts per billion (ppb) (normal <39 bbp). Bronchoalveolar lavage (BAL) demonstrated eosinophilia. CT of the sinuses, infectious workup, anti-cyclic citrullinated peptide antibody (CCP), and genetic testing for hypereosinophilia were negative. Treatment with prednisone and Mepolizumab months led to significant improvement of respiratory symptoms.Case 2: A 69-year-old man with refractory allergic rhinitis and chronic sinusitis, gastroesophageal reflux (GERD) presented with eight years of chronic productive cough, dyspnea on exertion, weight loss, dysphagia. Labs noted peripheral eosinophilia, elevated IgE, isolated P-ANCA positivity. CT chest noted peripheral predominant reticulations, traction bronchiectasis, and ground-glass opacities indeterminate for UIP. PFTs noted severe restrictive pattern with reduced DLCO. ENO was elevated at 54 ppb (normal <30 ppb). CT of sinuses noted bilateral mucosal thickening and polyps. BAL and biopsies were unable to be performed prior to prednisone initiation given severity of symptoms and hypoxemia. Prednisone led to dramatic symptom improvement. Mepolizumab initially added but discontinued due to side effects and he denied Mycophenolate due to concern for side effects.Discussion: While pulmonary fibrosis in patients with P-ANCA and MPO positive microscopic polyangiitis (MPA) has been well described, it is rare in EGPA. In cases of ILD associated with EGPA, usual interstitial pneumonia (UIP) is the most common imaging finding, with nonspecific interstitial pneumonia (NSIP) and unclassified interstitial lung disease (ILD) also reported. Fibrosis develops either secondary to eosinophilic release of profibrotic and inflammatory cytokines and deficiency of anti-inflammatory neutrophil extracellular traps (NET), as described with idiopathic eosinophilic pneumonia, or due to overlap with MPA. Similar to MPA, fibrosis in our cases preceded development of systemic vasculitis, although many cases of AAV with pulmonary fibrosis report concomitant systemic vasculitis. Despite adequate initial treatment, fibrosis may progress, requiring antifibrotics.
Idiopathic CD4 Lymphocytopenia: A Rare Immunodeficiency Disorder
Rashid, Sheikh Abdur , Baqir, M., Ahmed, N., Rashid, S., Baqir, M., Warrington, Kenneth J.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3583-A3583

10.1164/ajrccm.2025.211.abstracts.a3583 Get It

Abstract Introduction: Idiopathic CD4 lymphocytopenia is a disorder with CD4 counts below 200 cells/mm3 or less than 20% of total lymphocytes without an acquired or genetic cause. Case Summary: A 41-year-old female with history of Celiac disease complicated by hyposplenism developed fevers, weight loss, sicca symptoms, widespread erythematous rash, sinusitis, multifocal pneumonia refractory to antibiotics and pulmonary embolism. Workup demonstrated isolated weakly positive PR3 antibody of 1.2 (reference range < 1.0), CD4 count of 78 with negative ANA, ENA, HIV, CMV, EBV, HTLV, fungal, mycobacterial testing and mildly low IgM. PET-CT noted FDG avidity in the paranasal sinuses, lung opacities and salivary glands. Sinus biopsy showed chronic inflammation and fibrosis. Sputum cultures were positive for MSSA and Pseudomonas. Lung biopsy noted fibrinous organizing pneumonia. Skin biopsy demonstrated pauci-inflammatory vacuolar interface dermatitis with discontinuous weak granular deposition of C3 on basement membrane. A small-intestinal biopsy noted villous blunting and polymorphous T cell infiltration of the lamina propria. Bone marrow biopsy redemonstrated polytypic T cells with inverted CD4:CD8 ratio, but neither harbored an abnormal T cell population. Treatment for presumptive GPA was undertaken with corticosteroids, Rituximab, and Avacopan with transient improvement. CRP was elevated at 65.1 mg/dL (reference range < 5.0mg/dL). However, CD4 count had increased to 260 (reference range 365-1437) with 20% CD4 cells, low B cells, normal CD8 and NK cells, and IgG4 levels elevated at 180 mg/dL (reference range 2.4-121.0). LDH was elevated at 455 U/L (reference range 122-222) but flow cytometry, SPEP, and FLC ratio were unremarkable. Rhinoscopy demonstrated purulence, nasal septal perforation, and crusting of the larynx and subglottis. Salivary gland biopsy noted chronic sialadenitis without malignancy. Repeat CD4 count was 93. Given recurrent, refractory pulmonary infections, IVIG was considered, but prior to administration the patient developed worsening hypoxemia and pressor requirements and was transitioned to comfort cares. Discussion: It is crucial to rule out conditions causing lymphopenia, such as severe sarcoidosis, Sjogren's, IgG4-related disease, cutaneous T cell lymphoma, and splenectomy. While common complications include opportunistic infections, invasive cancers and autoimmunity, their absence may be explained by normal CD3 and CD8 counts. Despite complications, mortality is generally not increased, although baseline CD4 counts of less than 150 cells/mm3 may predict death. Decreases in CD4 counts in the setting of rising immunoglobulin levels may represent antibody production against lymphocytes. While evidence on the use of IVIG is limited, it may be beneficial when hypogammaglobulinemia or life-threatening infections are present.
Incidence of Eosinophilic Inflammation in Bronchiectasis Varies Significantly With Blood Eosinophil Count Assessment Strategy
Alitelat, Alwatheq , Labban, M. El, Doumat, Georgina , Chalmers, Sarah , Aksamit, T.R., Kanj, Amjad

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3466-A3466

10.1164/ajrccm.2025.211.abstracts.a3466 Get It

Abstract RATIONALE: Absolute Blood Eosinophil Counts (BEC) in bronchiectasis patients offer insights into inflammatory patterns and potential treatments. In non-cystic fibrosis bronchiectasis (NCFB), BEC≥300 cells/μL characterizes Eosinophilic Bronchiectasis (EB), a type-2 inflammation endotype estimated in 20% of patients. Guidance on BEC assessment strategy (i.e., number, frequency and timing of BEC≥300 defining this endotype) is unclear. We hypothesize that EB incidence varies by BEC≥300 assessment strategy. We also investigate eosinophilic inflammation in CF for comparison. Objectives: Assess BEC≥300 incidence in NCFB and CF cohorts. METHODS: From January 2023 to October 2024, BEC were measured in 9,953 stable bronchiectasis patients across Mayo Clinic, including 9,806 with NCFB (J47.9; 66,780 CBCs) and 147 with CF (E84.0; 1,405 CBCs). Incidence of BEC≥300 was evaluated in relation to CBC frequency and timing (i.e., BEC≥300 on first, second, last, any, any two, first two simultaneously) and the number of CBCs per patient. RESULTS: In the NCFB cohort, median age was 74 years (IQR:66-82), with 59.5% female. Median CBCs/patient was 3 (IQR:1-7). Incidence of BEC≥300 on the first CBC was 19.8%. Among patients with ≥2 CBCs (n=7,075), incidence was 20.1% on the first, 19.8% on the second, and 20.0% on the last. This incidence rose to 36.3% when considering any CBC/patient. BEC≥300 on at least two CBCs was 29.3%, decreasing to 11.8% when considering consecutive BEC≥300 on both first and second CBCs. The incidence of BEC≥300 increased linearly with the number of CBCs obtained: 24.6% for those with 1-3 CBCs, up to 64.6% for >12 CBCs. In the CF cohort, median age was 36 years (IQR:27-52), with 55.1% female. Median CBCs/patient was 4 (IQR:2-8). BEC≥300 was present in 22.9% of first CBCs, rising to 36.3% when considering any CBC and 29.3% when present on at least two CBCs. Similar to the NCFB cohort, incidence increased with the number of CBCs: 26.5% for 1-3, up to 77.3% for >12. CONCLUSIONS: The incidence of BEC≥300 in our NCFB cohort remained steady at 20% at any specific measurement point, consistent with prospective literature. However, nearly half of those with BEC≥300 on the first or second CBC did not meet this threshold on both. Incidence significantly increased when any CBC was considered, and more CBCs were available. Similar observations were made in the CF cohort. Clearer BEC assessment strategies are needed to define clinically significant eosinophilic inflammation in bronchiectasis, to better identify patients who may most benefit from type 2 inflammation-targeted treatments.
Aspergillus SP. Positive Airway Samples in People With Non-CF Bronchiectasis is Associated With Higher Biomarkers of Systemic TH2 Inflammation, Allergic Airway Disease, and Airway Co-infection
Poore, T., McShane, Pamela J. , Aksamit, T.R., Richards, C. , Ignatius, Elisa H. , Poore, T. Spencer , Brunton, Amanda E. , Swenson, Colin , Solomon, George M

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3451-A3451

10.1164/ajrccm.2025.211.abstracts.a3451 Get It

Abstract Introduction: Non-Cystic Fibrosis Bronchiectasis (NCFB) is an obstructive pulmonary disease associated with structural lung disease, altered mucociliary clearance, hyper mucus secretion, recurrent infection, and airway inflammation that results in significant morbidity and mortality. Aspergillus sp (Asp) is a common fungi isolated in respiratory specimens of those with lung disease and is associated with both infectious and allergic pulmonary diseases such as Asthma and Cystic Fibrosis. Despite individuals with NCFB having similar phenotypes as these conditions, the impact of Asp on this population is poorly understood. Methods: We performed a cross-sectional retrospective analysis from the US Bronchiectasis and NTM Research Registry (BRR). NCFB patients without a history of lung transplant who had at least one respiratory Asp culture were included. We compared patients with no history of Asp grown from respiratory culture to those with at least one positive respiratory culture for Asp during the available period. Patient demographics, bacterial culture history, lung function, comorbidities, modified Bronchiectasis Severity Index (mBSI), and sputum parameters were analyzed descriptively. Comparisons between groups were conducted using Kruskal-Wallis, independent sample t-tests, and chi-square tests for continuous and categorical variables as appropriate. Results: 3985 people with NCFB met inclusion criteria. 3359 (84.3%) individuals were Asp culture negative compared to 626 (15.7%) individuals with Asp. There were notable differences in race, showing higher proportions of non-Hispanic white (90.4 vs 82.2%) in this population. While the frequency of Chronic Obstructive Pulmonary Disease and Primary Ciliary Dyskinesia were similar, there were more individuals with Asthma (31.3 vs 24.7%, p<0.001) and Allergic Bronchopulmonary Aspergillosis (ABPA) (6.4 vs 2.4%, p<0.001) in the Asp positive group (Figure 1A). The Asp positive group had higher blood eosinophils (150.0 vs 124.0 cells/uL, p=0.026, Figure 1B), had nominally lower lung function (73.5 vs 75.3% ppFEV1, p=0.089), and were more likely to have at least one or more positive bacterial cultures (62.9 vs 51.9%, p<0.001, Figure 1C). There was no significant difference in sex, age, exacerbations, Pseudomonas aeruginosa or NTM positive cultures, sputum volume, or mBSI. Conclusion: Individuals with NCFB and history of one or more positive Asp cultures were more likely to be non-Hispanic white, have a diagnosis of Asthma and/or ABPA, higher blood eosinophils, and more positive airway bacterial cultures. Further work is needed to better understand how Asp contributes to bronchiectasis progression. More expansive analysis and multivariant modeling is underway to better understand the impact of Asp in people with NCFB.
Effect of Social Deprivation on Asthma Phenotype Varies by Sex and Race
Solanki, N. , Comhair, Suzy , Zein, Joe , Bleecker, Eugene R., Denlinger, Loren C. , Jarjour, N.N., Mauger, D. , Meyers, Deborah A. , Moore, W.C., Erzurum, Serpil C. , Fahy, John V. , Tsuang, Wayne , Castro, Mario , Levy, Bruce David , Wenzel, Sally E.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3440-A3440

10.1164/ajrccm.2025.211.abstracts.a3440 Get It

Abstract Introduction: The airway inflammation of asthma is characterized by immune phenotypes, often classified as Type 2 inflammation high or low. Social determinants of health (SDoH) can influence asthma risk and severity, but whether or not SDoH influence immune phenotypes is unclear. The social deprivation index (SDI) is a composite measure of seven neighborhood level characteristics: poverty level, less than 12 years of education, single parent household, living in rented housing unit, living in overcrowded housing unit, households without a car, and non-employed adults under 65 years of age. The scale of SDI ranges from 1 to 100, correlating with increasing deprivation. We hypothesized that social deprivation influences immune phenotype of asthma, and that deprivation effects vary by sex and race. Methods: Using the American Community Survey summary file spanning 2015 to 2019, we linked SDI to participant zip codes for 680 Black and White participants in the Severe Asthma Research Program (SARP), a NHLBI-multicenter network phenotyping asthma across the US from 2001-2024 (table 1). We compared SDI among the cohort by sex, race and asthma severity, and correlated SDI to superoxide dismutase (SOD) and T2-high biomarkers, such as eosinophils, IgE and Fraction of Exhaled Nitric Oxide (FENO). Results: SDI is similar across healthy and asthmatic participants (SDI: median [interquartile range]: healthy: 40 [56]; asthmatics: 51 [53], P = 0.53). When evaluated by race, SDI is significantly higher in Black asthmatics, independent of sex (SDI: Black male: 76 [4], White male: 35 [45]; P<0.0001; Black females: 77 [35], White females: 40 [45]; P<0.00010). Within SARP asthmatics, SDI shows a positive association with the T2 inflammatory markers, log IgE (R=0.13 [90%CI: 0.1, 0.2)] and log FENO (R=0.15 [90%CI: 0.1, 0.2]), while it correlates negatively with log of absolute neutrophil count (R= -0.12 [90%CI: -0.19,-0.1]). The antioxidant enzyme SOD increases with SDI (R=0.11, [90% CI: 0.04, 0.17]). Notably, within Black asthmatic males only, SDI is associated with Type 2 biomarkers, showing a positive correlation with log FENO (R=0.24 [90%CI: 0.1,0.4]) and negative correlation with log IgE levels (R= -0.25, [90% CI: -0.4, -0.1]). No association was found between SDI and eosinophils or with SOD in Black males. Conclusions: Neighborhood level social deprivation is associated with a unique asthma phenotype in Black males. Black males living at high social deprivation have a lower IgE and higher FENO, with no change in SOD activity.